Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and ...
Catalyst Pharmaceuticals is a biopharmaceutical...
Recro Pharma (NASDAQ: REPH) is a revenue generating specialty pharmaceutical compa...
Recro Pharma (NASDAQ: REPH) is a revenue genera...
NeuBase Therapeutics, Inc. is developing its modular peptide-nucleic acid antisens...
NeuBase Therapeutics, Inc. is developing its mo...
Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, ...
Galapagos develops therapies with proprietary, ...
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on th...
G1 Therapeutics, Inc., is a clinical-stage biop...
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting the ...
Salarius Pharmaceuticals, Inc. is a clinical-st...
Vir integrates diverse innovations in science, technology, and medicine to transfo...
Vir integrates diverse innovations in science, ...
Join the National Investor Network and get the latest information with your interests in mind.